Silencing or stimulation? siRNA delivery and the immune system.

@article{Whitehead2011SilencingOS,
  title={Silencing or stimulation? siRNA delivery and the immune system.},
  author={Kathryn A. Whitehead and James E. Dahlman and Robert S. Langer and Daniel G. Anderson},
  journal={Annual review of chemical and biomolecular engineering},
  year={2011},
  volume={2},
  pages={
          77-96
        }
}
Since its inception more than a decade ago, the field of short interfering RNA (siRNA) therapeutics has demonstrated potential in the treatment of a wide variety of diseases. The power behind RNA interference (RNAi) therapy lies in its ability to specifically silence target genes of interest. As more biological data have become available, it has become evident that, in addition to mediating RNAi, siRNA molecules have the potential to potently induce the innate immune system. One of the… Expand
RNA Interference: Molecular mechanism and milestone therapeutic applications
TLDR
Modern understanding is focused on the mechanisms and therapeutic applications of RNAi, a set of reactions involving the sequence-specific degradation of targeted mRNA by short double-stranded RNA molecules. Expand
Triggering RNAi with multifunctional RNA nanoparticles and their delivery
TLDR
Different types of RNAi therapeutic delivery strategies including multifunctional RNA nanoparticles are being developed, and a mini-review will briefly describe some of the current approaches. Expand
Polymers in the Delivery of siRNA for the Treatment of Virus Infections
Viral diseases remain a major cause of death worldwide. Despite advances in vaccine and antiviral drug technology, each year over three million people die from a range of viral infections.Expand
Polymers in the Delivery of siRNA for the Treatment of Virus Infections
Viral diseases remain a major cause of death worldwide. Despite advances in vaccine and antiviral drug technology, each year over three million people die from a range of viral infections.Expand
Controlled local delivery of RNA : regulating tissue morphogenesis
TLDR
The local delivery of siRNA may hold just as much potential as systemic delivery with significantly reduced complications and could be combined with existing medical devices to improve patient outcomes by directly addressing pathologic problems. Expand
Stability and immunogenicity properties of the gene-silencing polypurine reverse Hoogsteen hairpins.
TLDR
Stability experiments revealed that PPRHs, unlike siRNAs, do not activate the innate inflammatory response, and a new type of molecule to decrease gene expression named polypurine reverse Hoogsteen hairpins that bind to polypyrimidine targets in the DNA was developed. Expand
Toward the therapeutic application of small interfering RNA bioconjugates in the central nervous system
TLDR
Specific delivery issues affecting therapeutic drug and nucleic acids delivery to the CNS are discussed, as well as some of the technological advancements on nucleic acid modifications and structural alterations applied to siRNA in the context of the bioconjugate systems approach. Expand
Nanotechnology for in vivo targeted siRNA delivery.
TLDR
Strategies for targeted siRNAs delivery are outlined, and how these strategies may be improved are described. Expand
Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy
TLDR
This article reviews the strategies that have been developed to facilitate siRNA survival in the circulatory system, siRNA movement from the blood into tissues and the TME, targeted siRNA delivery to the tumor or specific cell types, cellular uptake, and escape from endosomal degradation. Expand
How to Tackle the Challenge of siRNA Delivery with Sequence-Defined Oligoamino Amides.
TLDR
Issues of polycations regarding toxicity, heterogeneity, and polydispersity can be overcome by solid-phase-assisted synthesis of sequence-defined cationic oligomers, which can mimic the dynamic and bioresponsive behavior of viruses. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 124 REFERENCES
Drug Delivery–mediated Control of RNA Immunostimulation
TLDR
It is demonstrated that innate immune activation caused by unmodified siRNA can have therapeutically relevant effects, and that these non-RNAi effects can be controlled through chemical modifications and drug delivery. Expand
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
TLDR
It is reported that synthetic siRNAs formulated in nonviral delivery vehicles can be potent inducers of interferons and inflammatory cytokines both in vivo in mice and in vitro in human blood. Expand
Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation.
TLDR
It is demonstrated that in a murine model of influenza infection, the antiviral activity of siRNA is due primarily to immune stimulation elicited by the active siRNA duplexes and is not the result of therapeutic RNA interference (RNAi) as previously reported. Expand
siRNA and innate immunity.
TLDR
The intracellular mechanisms of innate immune activation by siRNA, the design of appropriate sequences and chemical modification approaches, and suitable experimental methods for studying their effects are described, with a view toward reducing siRNA-mediated off-target effects. Expand
Rational design of immunostimulatory siRNAs.
TLDR
The introduction of a micro-RNA-like nonpairing uridine-bulge in the passenger strand robustly increased immunostimulatory activity on human immune cells, and the data suggest that this sequence modification coupled with structural modification differentially recruits human TLR8 over TLR7, and could have potential application in antiviral therapies. Expand
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.
TLDR
It is shown that immune stimulation by synthetic siRNA can be completely abrogated by selective incorporation of 2'-O-methyl (2'OMe) uridine or guanosine nucleosides into one strand of the siRNA duplex, enabling therapeutically viable siRNA doses without cytokine induction, toxicity, or off-target effects associated with the use of unmodified siRNA. Expand
The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence.
TLDR
This chapter will explore the limitations and possibilities of LNA-modified siRNA that may be used in future therapeutic applications, and initial studies show that minimal modifications with locked nucleic acids (LNA) help to reduce most of the unwanted side effects. Expand
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.
TLDR
Preclinical development of chemically modified siRNA targeting the essential cell-cycle proteins polo-like kinase 1 (PLK1) and kinesin spindle protein (KSP) in mice is described, suggesting a new methodology for targeting other key genes in cancer development with siRNA-based therapeutics. Expand
Lack of interferon response in animals to naked siRNAs
TLDR
It is shown here that it is possible to administer naked, synthetic siRNAs to mice and downregulate an endogenous or exogenous target without inducing an interferon response. Expand
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
TLDR
Evidence is provided of inducing an RNAi mechanism of action in a human from the delivered siRNA and the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for anRNAi mechanism from a patient who received the highest dose of the nanoparticles. Expand
...
1
2
3
4
5
...